A new engineered protein called FD03-sST2 significantly improved kidney function in diabetic mice by blocking two harmful processes simultaneously: fat accumulation in kidney cells and inflammation. According to Gram Research analysis of this 2026 study, the treatment reduced kidney damage markers, lowered blood lipids, and prevented kidney scarring through dual inhibition of ANGPTL3 and IL-33 pathways. While promising, this is early-stage animal research requiring human trials before clinical use.
Researchers have developed a new treatment that fights diabetic kidney disease by targeting two different biological pathways at once. The study, published in Advanced Science in 2026, tested a specially designed protein called FD03-sST2 in mice with diabetes. According to Gram Research analysis, this dual-action approach reduced kidney damage by addressing both fat buildup in kidney cells and the inflammation that follows. The treatment improved kidney function markers and reduced harmful lipid levels. This research suggests a promising new direction for treating diabetic kidney disease, which currently affects millions of people worldwide and often progresses despite existing medications.
Key Statistics
A 2026 research study in Advanced Science found that FD03-sST2, a dual-action protein, significantly improved kidney function markers including albumin in urine and blood urea nitrogen levels in diabetic mice with kidney disease.
According to a 2026 animal study, the engineered protein FD03-sST2 reduced kidney fat accumulation and suppressed inflammation through dual inhibition of ANGPTL3 and IL-33 pathways in diabetic mice.
A 2026 research article demonstrated that targeting both lipid metabolism (ANGPTL3) and inflammation (IL-33) simultaneously with a single protein reduced kidney scarring and prevented fibrosis progression in diabetic kidney disease models.
The Quick Take
- What they studied: Whether a new engineered protein that blocks two different harmful processes could prevent kidney damage in diabetic mice
- Who participated: High-fat diet-fed diabetic mice (db/db mice), a standard model used to study human diabetes and kidney disease
- Key finding: The new protein treatment significantly improved kidney function, reduced fat accumulation in kidneys, and decreased inflammation and scarring compared to untreated diabetic mice
- What it means for you: This research suggests a potential new treatment strategy for diabetic kidney disease that works differently than current medications. However, this is early-stage research in mice, so human trials would be needed before this becomes available as a treatment
The Research Details
Researchers created a new protein called FD03-sST2 that combines two different therapeutic functions into one molecule. The protein was designed to block ANGPTL3 (a protein that controls fat metabolism) and IL-33 (a protein that triggers inflammation). They tested this protein in genetically modified mice that develop diabetes and kidney disease similar to humans. The mice were fed a high-fat diet to mimic the conditions that worsen diabetic kidney disease in people.
The researchers measured multiple markers of kidney health, including albumin in urine (a sign of kidney damage), blood urea nitrogen (a waste product that builds up when kidneys fail), and urine volume. They also examined kidney tissue under microscopes and used advanced molecular techniques to understand exactly how the treatment worked at the cellular level.
This approach is important because it addresses multiple problems at once rather than targeting just one pathway. Diabetic kidney disease involves a complex chain of events where fat buildup triggers inflammation, which then causes scarring and permanent damage. By blocking two key steps in this chain simultaneously, the treatment interrupts the harmful cycle at multiple points.
Current diabetes medications control blood sugar and blood pressure but don’t stop kidney disease from progressing in many patients. This research identifies a new mechanism—the combination of fat accumulation and inflammation—that drives kidney damage independently of blood sugar control. By targeting this mechanism with a single engineered protein rather than multiple separate drugs, the treatment could be simpler for patients to use and might work better by addressing the root causes rather than just symptoms.
This is laboratory research using animal models, which is an important first step but doesn’t directly prove the treatment will work in humans. The study appears to be well-designed with multiple measurement methods and molecular analysis to confirm the findings. The use of a specialized mouse model that closely mimics human diabetic kidney disease strengthens the relevance of the results. However, animal studies often show more dramatic results than human trials, so realistic expectations are important.
What the Results Show
The FD03-sST2 protein treatment produced significant improvements in kidney function in diabetic mice. Albumin in the urine—a key marker of kidney damage—was substantially reduced, indicating the kidneys were filtering better. Blood urea nitrogen levels decreased, showing that kidney function improved. The treatment also reduced urine volume abnormalities that occur in diabetic kidney disease.
Beyond kidney function, the treatment reduced fat accumulation in the kidneys themselves and lowered harmful fat levels in the blood and liver. This is important because fat buildup in kidney cells (called lipotoxicity) is thought to be a major driver of kidney damage in diabetes. The treatment also reduced inflammation markers in the kidneys, particularly by blocking a pathway called NF-κB/NLRP3 that triggers inflammatory responses.
The treatment also reduced kidney scarring (fibrosis), which is the permanent damage that eventually leads to kidney failure. This occurred through suppression of the IL-33/ST2 pathway, which normally triggers immune cells to produce scar-forming substances. By blocking this pathway, the treatment prevented the cascade of events that leads to permanent kidney damage.
Additional analysis showed that the treatment reduced specific inflammatory signals in kidney tissue, particularly those involving immune cells called ILC2s. The researchers used advanced molecular techniques to examine gene expression patterns and metabolic changes in kidney tissue, confirming that the treatment normalized many of the abnormal patterns seen in diabetic kidney disease. These findings suggest the treatment works through the mechanisms the researchers predicted.
Previous research has shown that blocking either ANGPTL3 or IL-33 alone provides some benefit in kidney disease models. This study advances that knowledge by showing that blocking both simultaneously provides greater benefit than either alone would likely provide. The dual-action approach addresses what researchers call a ‘vicious cycle’ where fat accumulation triggers inflammation, which then worsens fat accumulation. By interrupting this cycle at two points, the treatment appears more effective than single-target approaches.
This research was conducted in mice, not humans, so results may not directly translate to human patients. The study used genetically modified mice on a high-fat diet, which models severe diabetes but may not represent all types of diabetic kidney disease in humans. The study did not compare the new treatment to existing diabetes medications, so it’s unclear how it would perform alongside current standard care. The exact dose and duration of treatment needed in humans is unknown. Additionally, potential side effects in humans have not been evaluated, and long-term safety data is not available.
The Bottom Line
This research is promising but preliminary. It suggests that targeting both fat metabolism and inflammation simultaneously may be an effective strategy for treating diabetic kidney disease. However, these findings are from animal studies and must be confirmed in human clinical trials before any recommendations can be made for patient care. People with diabetic kidney disease should continue following their doctor’s current treatment plans while this research progresses toward human testing.
This research is most relevant to people with type 2 diabetes who have or are at risk for kidney disease, as well as researchers and pharmaceutical companies developing new treatments. It may also interest healthcare providers treating diabetic kidney disease. People with other types of kidney disease should not assume these findings apply to their condition without further research.
This is early-stage research. If the treatment moves forward, it would typically take 5-10 years of additional research, including human safety trials and effectiveness studies, before it could potentially become available as a treatment. Realistic expectations are that this is a promising direction that requires substantial additional work before clinical use.
Frequently Asked Questions
What causes kidney damage in people with diabetes?
High blood sugar and high blood pressure are the main causes, but research shows fat buildup in kidney cells and chronic inflammation also drive kidney damage. This new study suggests blocking both fat accumulation and inflammation may help prevent kidney disease progression in diabetic patients.
When will this new diabetic kidney disease treatment be available?
This is early-stage research in mice. If development continues successfully, human safety trials would typically begin in 2-3 years, with potential availability 5-10 years away. Current diabetes medications remain the standard treatment for now.
How does this new treatment work differently than current diabetes medications?
Current medications control blood sugar and blood pressure. This new treatment targets fat accumulation and inflammation in kidney cells directly, addressing different mechanisms of kidney damage. It may work alongside existing medications rather than replacing them.
Can this treatment help people who already have kidney damage from diabetes?
The study showed the treatment reduced kidney scarring in mice, suggesting it might help prevent further damage. However, this is animal research only. Human studies would be needed to determine if it can reverse existing kidney damage or only prevent progression.
What should people with diabetic kidney disease do now based on this research?
Continue following your doctor’s current treatment plan, including blood sugar control, blood pressure management, and kidney function monitoring. Stay informed about new research, but don’t expect this treatment to be available soon. Discuss any questions with your healthcare provider.
Want to Apply This Research?
- Users with diabetes could track kidney health markers through their healthcare provider: measure urine albumin levels monthly and blood creatinine/eGFR quarterly to monitor kidney function trends over time
- Set reminders to maintain consistent diabetes management (medication adherence, blood sugar monitoring, blood pressure control) while this research progresses, as current treatments remain important for kidney protection
- Create a quarterly health tracking log documenting kidney function test results, blood pressure readings, and diabetes control metrics to share with healthcare providers and monitor disease progression
This article summarizes early-stage laboratory research in animals and should not be interpreted as medical advice or a treatment recommendation. Diabetic kidney disease is a serious condition requiring ongoing medical care from qualified healthcare providers. Current standard treatments for diabetes and kidney disease should be continued as prescribed. Anyone with diabetes or kidney disease should discuss new research findings with their doctor before making any changes to their treatment plan. This research has not been tested in humans, and results in animals do not guarantee similar outcomes in people. Always consult with your healthcare provider before starting any new treatment or making significant health decisions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.